EMA-话题@MedSci

#EMA#

580篇内容 | 2475人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1317692, encodeId=8d66131e692af, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Lancet Haematol：与NICU的重症新生儿动静脉血栓形成相关的风险因素！, objectType=article, longId=295443, objectId=60452954435e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=60452954435e, replyNumber=0, likeNumber=74, createdTime=2022-02-12, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=60452954435e, moduleTitle=Lancet Haematol：与NICU的重症新生儿动静脉血栓形成相关的风险因素！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=60452954435e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317691, encodeId=e959131e69125, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Ann Hematol：造血干细胞移植患者的固定剂量给药和药代动力学指导调整白消安剂量具有更高的功效、安全性和成本效益, objectType=article, longId=295383, objectId=932c295383ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=932c295383ba, replyNumber=0, likeNumber=116, createdTime=2022-02-11, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=932c295383ba, moduleTitle=Ann Hematol：造血干细胞移植患者的固定剂量给药和药代动力学指导调整白消安剂量具有更高的功效、安全性和成本效益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=932c295383ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317690, encodeId=ba1f131e69092, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Lancet Haematol：Melflufen联合地塞米松治疗复发性或难治性多发性骨髓瘤, objectType=article, longId=295220, objectId=fab329522003, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fab329522003, replyNumber=0, likeNumber=86, createdTime=2022-02-08, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fab329522003, moduleTitle=Lancet Haematol：Melflufen联合地塞米松治疗复发性或难治性多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fab329522003)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317689, encodeId=1580131e68968, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=HAEMATOLOGICA：自体干细胞移植对健康的老年骨髓瘤患者安全有效：骨髓瘤 XI 试验的探索性结果, objectType=article, longId=295119, objectId=7619295119a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7619295119a4, replyNumber=0, likeNumber=70, createdTime=2022-02-05, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7619295119a4, moduleTitle=HAEMATOLOGICA：自体干细胞移植对健康的老年骨髓瘤患者安全有效：骨髓瘤 XI 试验的探索性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7619295119a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317688, encodeId=50b4131e688d2, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=EMA建议对辉瑞的Paxlovid进行有条件授权, objectType=article, longId=295113, objectId=1cec29511340, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1cec29511340, replyNumber=0, likeNumber=63, createdTime=2022-02-05, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1cec29511340, moduleTitle=EMA建议对辉瑞的Paxlovid进行有条件授权, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1cec29511340)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317687, encodeId=eb8c131e687b5, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Haematologica：基于真实世界的评分来预测急性早幼粒细胞白血病的早期死亡, objectType=article, longId=295016, objectId=30c2295016fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=30c2295016fa, replyNumber=0, likeNumber=100, createdTime=2022-02-03, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=30c2295016fa, moduleTitle=Haematologica：基于真实世界的评分来预测急性早幼粒细胞白血病的早期死亡, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=30c2295016fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317686, encodeId=29d1131e686a7, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Hematology：与 ICU 入院治疗急性白血病相关的患者生命体征：回顾性图表回顾。, objectType=article, longId=294606, objectId=17a129460635, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=17a129460635, replyNumber=0, likeNumber=69, createdTime=2022-01-25, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=17a129460635, moduleTitle=Hematology：与 ICU 入院治疗急性白血病相关的患者生命体征：回顾性图表回顾。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=17a129460635)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317685, encodeId=d45c131e68590, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=A&R: Semaphorin3B 在血清诱导的关节炎模型中起核心作用，在类风湿性关节炎患者中降低, objectType=article, longId=294440, objectId=85cd29444097, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=85cd29444097, replyNumber=0, likeNumber=83, createdTime=2022-01-23, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=85cd29444097, moduleTitle=A&R: Semaphorin3B 在血清诱导的关节炎模型中起核心作用，在类风湿性关节炎患者中降低, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=85cd29444097)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317684, encodeId=c70c131e6840b, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Leman Micro Devices：世界临床试验证明，无袖带移动设备传感器及其应用程序测量血压的准确度与袖带式设备相同, objectType=article, longId=293936, objectId=86a329393661, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=86a329393661, replyNumber=0, likeNumber=75, createdTime=2022-01-14, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=86a329393661, moduleTitle=Leman Micro Devices：世界临床试验证明，无袖带移动设备传感器及其应用程序测量血压的准确度与袖带式设备相同, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=86a329393661)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317683, encodeId=9f3a131e6830d, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Acta Haematol：成功治疗 26 岁女性患者疫苗引起的免疫性血栓性血小板减少症, objectType=article, longId=293608, objectId=7f392936087d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7f392936087d, replyNumber=0, likeNumber=76, createdTime=2022-01-09, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7f392936087d, moduleTitle=Acta Haematol：成功治疗 26 岁女性患者疫苗引起的免疫性血栓性血小板减少症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7f392936087d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317682, encodeId=619c131e68279, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Lancet Haematol：全反式视黄酸加大剂量地塞米松可作为新诊断免疫性血小板减少症患者的一线治疗, objectType=article, longId=293423, objectId=5f6429342357, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5f6429342357, replyNumber=0, likeNumber=95, createdTime=2022-01-06, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5f6429342357, moduleTitle=Lancet Haematol：全反式视黄酸加大剂量地塞米松可作为新诊断免疫性血小板减少症患者的一线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5f6429342357)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317681, encodeId=5f51131e6812d, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Haematol：达雷妥尤单抗可能用于多发性难治性自身免疫性血细胞减少症, objectType=article, longId=293385, objectId=f20f29338534, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f20f29338534, replyNumber=0, likeNumber=76, createdTime=2022-01-05, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f20f29338534, moduleTitle=Haematol：达雷妥尤单抗可能用于多发性难治性自身免疫性血细胞减少症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f20f29338534)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317680, encodeId=91cd131e680a7, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Ann Hematol：在卡帕珠单抗前时代获得性血栓性血小板减少性紫癜的死亡率, objectType=article, longId=293184, objectId=ac6f29318456, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ac6f29318456, replyNumber=0, likeNumber=74, createdTime=2022-01-01, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ac6f29318456, moduleTitle=Ann Hematol：在卡帕珠单抗前时代获得性血栓性血小板减少性紫癜的死亡率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ac6f29318456)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317679, encodeId=16c1131e67925, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Haematologica：Isatuximab 加卡非佐米和地塞米松与卡非佐米和地塞米松在肾功能不全的复发性多发性骨髓瘤患者中的比较, objectType=article, longId=292200, objectId=8c42292200d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8c42292200d9, replyNumber=0, likeNumber=66, createdTime=2021-12-20, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8c42292200d9, moduleTitle=Haematologica：Isatuximab 加卡非佐米和地塞米松与卡非佐米和地塞米松在肾功能不全的复发性多发性骨髓瘤患者中的比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8c42292200d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317678, encodeId=25a5131e67894, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=HAEMATOLOGICA：口服阿扎胞苷为缓解期急性髓系白血病患者保持良好的疲劳水平和健康相关的生活质量, objectType=article, longId=292199, objectId=bd9029219911, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bd9029219911, replyNumber=0, likeNumber=73, createdTime=2021-12-20, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bd9029219911, moduleTitle=HAEMATOLOGICA：口服阿扎胞苷为缓解期急性髓系白血病患者保持良好的疲劳水平和健康相关的生活质量, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bd9029219911)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317677, encodeId=d192131e6777f, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=新Sci-Hub来了，2亿免费全文文献！Semantic Scholar 详细介绍, objectType=article, longId=291788, objectId=6597291e885d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6597291e885d, replyNumber=0, likeNumber=75, createdTime=2021-12-15, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6597291e885d, moduleTitle=新Sci-Hub来了，2亿免费全文文献！Semantic Scholar 详细介绍, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6597291e885d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317676, encodeId=851e131e67690, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Ann Oncol：内分泌联合或不联合abemaciclib（阿贝西利）辅助治疗HR+/HER2-早期高危乳腺癌患者的疗效, objectType=article, longId=221443, objectId=d7bd22144352, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d7bd22144352, replyNumber=0, likeNumber=70, createdTime=2021-12-04, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d7bd22144352, moduleTitle=Ann Oncol：内分泌联合或不联合abemaciclib（阿贝西利）辅助治疗HR+/HER2-早期高危乳腺癌患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d7bd22144352)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317675, encodeId=27a0131e6757a, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=EMA 收到molnupiravir的上市许可申请, objectType=article, longId=221249, objectId=935822124991, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=935822124991, replyNumber=0, likeNumber=70, createdTime=2021-12-01, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=935822124991, moduleTitle=EMA 收到molnupiravir的上市许可申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=935822124991)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317674, encodeId=019e131e6743d, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=J Hematol Oncol：近30年全球29种癌症的发生率及死亡率, objectType=article, longId=221243, objectId=b59b22124326, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b59b22124326, replyNumber=0, likeNumber=73, createdTime=2021-11-30, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b59b22124326, moduleTitle=J Hematol Oncol：近30年全球29种癌症的发生率及死亡率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b59b22124326)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317673, encodeId=4b0a131e67360, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Exp Hematol：急性髓系白血病化疗损伤后免疫成分及其与血液学恢复的关系, objectType=article, longId=221211, objectId=9d8822121189, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9d8822121189, replyNumber=0, likeNumber=78, createdTime=2021-11-30, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9d8822121189, moduleTitle=Exp Hematol：急性髓系白血病化疗损伤后免疫成分及其与血液学恢复的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9d8822121189)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

EMA

2020-05-29

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Lancet Haematol：与NICU的重症新生儿动静脉血栓形成相关的风险因素！

2022-02-12

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Ann Hematol：造血干细胞移植患者的固定剂量给药和药代动力学指导调整白消安剂量具有更高的功效、安全性和成本效益

2022-02-11

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Lancet Haematol：Melflufen联合地塞米松治疗复发性或难治性多发性骨髓瘤

2022-02-08

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

HAEMATOLOGICA：自体干细胞移植对健康的老年骨髓瘤患者安全有效：骨髓瘤 XI 试验的探索性结果

2022-02-05

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

EMA建议对辉瑞的Paxlovid进行有条件授权

2022-02-05

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Haematologica：基于真实世界的评分来预测急性早幼粒细胞白血病的早期死亡

2022-02-03

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Hematology：与 ICU 入院治疗急性白血病相关的患者生命体征：回顾性图表回顾。

2022-01-25

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

A&R: Semaphorin3B 在血清诱导的关节炎模型中起核心作用，在类风湿性关节炎患者中降低

2022-01-23

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Leman Micro Devices：世界临床试验证明，无袖带移动设备传感器及其应用程序测量血压的准确度与袖带式设备相同

2022-01-14

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Acta Haematol：成功治疗 26 岁女性患者疫苗引起的免疫性血栓性血小板减少症

2022-01-09

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Lancet Haematol：全反式视黄酸加大剂量地塞米松可作为新诊断免疫性血小板减少症患者的一线治疗

2022-01-06

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Haematol：达雷妥尤单抗可能用于多发性难治性自身免疫性血细胞减少症

2022-01-05

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Ann Hematol：在卡帕珠单抗前时代获得性血栓性血小板减少性紫癜的死亡率

2022-01-01

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Haematologica：Isatuximab 加卡非佐米和地塞米松与卡非佐米和地塞米松在肾功能不全的复发性多发性骨髓瘤患者中的比较

2021-12-20

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

HAEMATOLOGICA：口服阿扎胞苷为缓解期急性髓系白血病患者保持良好的疲劳水平和健康相关的生活质量

2021-12-20

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

新Sci-Hub来了，2亿免费全文文献！Semantic Scholar 详细介绍

2021-12-15

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Ann Oncol：内分泌联合或不联合abemaciclib（阿贝西利）辅助治疗HR+/HER2-早期高危乳腺癌患者的疗效

2021-12-04

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

EMA 收到molnupiravir的上市许可申请

2021-12-01

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

J Hematol Oncol：近30年全球29种癌症的发生率及死亡率

2021-11-30

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Exp Hematol：急性髓系白血病化疗损伤后免疫成分及其与血液学恢复的关系

2021-11-30

科室
- - 订阅+
  - 更多科室
工具
服务